- conflicts or gaps
- [[{"field": {"value": "identity.website", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json", "https://www.yourchoicetx.com/", "https://www.sbir.gov/awards/175752"]}, "issue": {"value": "YC/OSS and SBIR list ychoicetx.com; current company site and 2024+ press use yourchoicetx.com.", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json", "https://www.yourchoicetx.com/", "https://www.sbir.gov/awards/175752"]}}, {"field": {"value": "employees.snapshots", "source_urls": ["https://www.ycombinator.com/companies/yourchoice-therapeutics", "https://pitchbook.com/profiles/company/266138-92", "https://www.linkedin.com/company/yourchoicetherapeutics", "https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE"]}, "issue": {"value": "Headcount varies: YC team_size 3 vs PitchBook 5 (2025) vs LinkedIn 6 vs Tracxn 7 (Mar 2026).", "source_urls": ["https://www.ycombinator.com/companies/yourchoice-therapeutics", "https://pitchbook.com/profiles/company/266138-92", "https://www.linkedin.com/company/yourchoicetherapeutics", "https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE/funding-and-investors", "https://www.cbinsights.com/company/yourchoice-therapeutics/financials", "https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/"]}, "issue": {"value": "Tracxn reports $15.2M (2 VC rounds only); CB Insights $15.65M over 5 rounds; third-party seed aggregators cite additional ~$1.6M Jan 2019 seed not confirmed in primary press. Grants/MCI non-dilutive funding inconsistently included.", "source_urls": ["https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE/funding-and-investors", "https://www.cbinsights.com/company/yourchoice-therapeutics/financials", "https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/"]}}, {"field": {"value": "founders", "source_urls": ["https://www.ycombinator.com/companies/yourchoice-therapeutics", "https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/"]}, "issue": {"value": "TechCrunch (Mar 2019) names Polina V. Lishko as co-founder and advisor; YC lists only Akash Bakshi and Nadja Mannowetz as founders.", "source_urls": ["https://www.ycombinator.com/companies/yourchoice-therapeutics", "https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/"]}}, {"field": {"value": "products", "source_urls": ["https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/", "https://www.dailycal.org/male-birth-control-pill-born-from-uc-berkeley-startup/article_3b66e7ee-fe78-419f-bc71-768afba5866d.html", "https://www.yourchoicetx.com/"]}, "issue": {"value": "2019 plan prioritized vaginal lupeol female product and 2025 market target; company pivoted to lead with oral male YCT-529 in clinic; female program remains future pipeline.", "source_urls": ["https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/", "https://www.dailycal.org/male-birth-control-pill-born-from-uc-berkeley-startup/article_3b66e7ee-fe78-419f-bc71-768afba5866d.html", "https://www.yourchoicetx.com/"]}}, {"field": {"value": "exit_status.clinical_milestones", "source_urls": ["https://www.businesswire.com/news/home/20240924791648/en/YourChoice-Therapeutics-Begins-Second-Human-Study-for-Hormone-Free-Male-Birth-Control-Pill"]}, "issue": {"value": "Business Wire headline references phase 1a/2b study; body text describes phase 1b/2a MAD study.", "source_urls": ["https://www.businesswire.com/news/home/20240924791648/en/YourChoice-Therapeutics-Begins-Second-Human-Study-for-Hormone-Free-Male-Birth-Control-Pill"]}}, {"field": {"value": "identity.hq_location", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json", "https://www.linkedin.com/company/yourchoicetherapeutics", "https://www.gaebler.com/VC-Funding-34E2638E-BDEC-47AD-9E81-5D0182FFB9A4-YourChoice-Therapeutics-07-21-2022"]}, "issue": {"value": "Sources split between San Francisco HQ (press, Gaebler mailing address 1460 Mission St) and Berkeley HQ (LinkedIn, SBIR awardee address, UC Berkeley origin).", "source_urls": ["https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json", "https://www.linkedin.com/company/yourchoicetherapeutics", "https://www.gaebler.com/VC-Funding-34E2638E-BDEC-47AD-9E81-5D0182FFB9A4-YourChoice-Therapeutics-07-21-2022", "https://www.sbir.gov/awards/175752"]}}, {"field": {"value": "funding.rounds[4].announced_at", "source_urls": ["https://www.axios.com/pro/health-tech-deals/2022/07/20/yourchoice-therapeutics-raises-15-million-series-a", "https://www.gaebler.com/VC-Funding-34E2638E-BDEC-47AD-9E81-5D0182FFB9A4-YourChoice-Therapeutics-07-21-2022"]}, "issue": {"value": "Series A announcement date reported as 2022-07-20 (Axios, YC) vs 2022-07-21 (Gaebler).", "source_urls": ["https://www.axios.com/pro/health-tech-deals/2022/07/20/yourchoice-therapeutics-raises-15-million-series-a", "https://www.gaebler.com/VC-Funding-34E2638E-BDEC-47AD-9E81-5D0182FFB9A4-YourChoice-Therapeutics-07-21-2022"]}}]]
- source urls
- ["https://femtechinsider.com/yourchoice-series-a/", "https://ipira.berkeley.edu/yourchoice-therapeutics", "https://pitchbook.com/profiles/company/266138-92", "https://pubmed.ncbi.nlm.nih.gov/40696162/", "https://techcrunch.com/2019/03/14/yourchoice-therapeutics-is-developing-unisex-non-hormonal-birth-control/", "https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE", "https://tracxn.com/d/companies/yourchoicetherapeutics/__tWNQMQqq4PYQcyGYpdNGGJ1Z4X1B1WUkjyScE4o9kkE/funding-and-investors", "https://www.axios.com/pro/health-tech-deals/2022/07/20/yourchoice-therapeutics-raises-15-million-series-a", "https://www.businesswire.com/news/home/20240924791648/en/YourChoice-Therapeutics-Begins-Second-Human-Study-for-Hormone-Free-Male-Birth-Control-Pill", "https://www.cbinsights.com/company/yourchoice-therapeutics/financials", "https://www.dailycal.org/male-birth-control-pill-born-from-uc-berkeley-startup/article_3b66e7ee-fe78-419f-bc71-768afba5866d.html", "https://www.eurekalert.org/news-releases/1112371", "https://www.gaebler.com/VC-Funding-34E2638E-BDEC-47AD-9E81-5D0182FFB9A4-YourChoice-Therapeutics-07-21-2022", "https://www.linkedin.com/company/yourchoicetherapeutics", "https://www.malecontraceptive.org/yourchoice-therapeutics.html", "https://www.newswire.com/news/male-contraceptive-initiative-marks-women-s-history-month-with-22276849", "https://www.sbir.gov/awards/175752", "https://www.ycombinator.com/companies/yourchoice-therapeutics", "https://www.yourchoicetx.com/", "https://yc-oss.github.io/api/batches/winter-2019/yourchoice-therapeutics.json"]